Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 14/20 | 0.51 |
| ▸ | THRA | P10827 | 7/20 | 0.51 |
| ▸ | RHEB | Q15382 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640579 | 0.91 | THRB (0.59) | THRBTHRARHEB | |
| SCHEMBL1640702 | 0.91 | THRB (0.47) | THRBTHRARHEBBRD4BRD2 | |
| SCHEMBL6272088 | 0.90 | THRB (0.43) | THRBTHRABRD4BRD2BRD3 | |
| SCHEMBL6794754 | 0.88 | THRB (0.46) | THRBTHRARHEBBRD4BRD2 | |
| SCHEMBL1641445 | 0.88 | THRB (0.58) | THRBTHRARHEBBRD4BRD2 | |
| SCHEMBL1642115 | 0.88 | THRB (0.47) | THRBTHRARHEBBRD4BRD2 | |
| SCHEMBL6795305 | 0.87 | THRB (0.47) | THRBTHRARHEBBRD4BRD2 | |
| SCHEMBL6269983 | 0.81 | THRB (0.47) | THRBTHRARHEBBRD4BRD2 | |
| SCHEMBL6274988 | 0.80 | THRB (0.51) | THRBTHRABRD4BRD2BRD3 | |
| SCHEMBL6273242 | 0.79 | THRB (0.49) | THRBTHRABRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1297833-B1 | Indole carboxylic acids as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-6723744-B2 | FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA | PFIZER, INC. | 2004-04-20 | — | — | US | disclosed |
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | ASPNES GARY E (US) | 2003-04-24 | — | — | US | disclosed |
| EP-1297833-A1 | Indole carboxylic acids as thyroid receptor ligands | Pfizer Products Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | THRA, MC1R, THRB | THRB 3/4885THRA 1/4885RHEB 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.